Breast CancerNCT07631962
Impact of Radiotherapy on Survival in Breast Cancer Patients
An observational study of Breast Cancer and Radiotherapy, run by Motamed Cancer Institute.
Trial summary
In this study, using a large retrospective cohort, the investigators evaluate the impact of RT on disease-free survival and overall survival of patients with BC. The aim is to determine the true role of radiotherapy in improving patient outcomes and to provide a basis for designing more precise treatment strategies in… Read more about this study
- Who is it for?
- Any age, women only
- Conditions the study is for
- Breast Cancer, Radiotherapy
- What is being tested?
- radiotherapy
- Type of treatment
- Surgery or procedure
- How many people
- 1,030 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 1998to 1 Jan 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- No healthy volunteers
- Child, Adult, Older adult
Study population: BC patients diagnosed between January 1998 and February 2008 were identified from prospectively maintained breast cancer registries in the Motamed Breast Cancer Research in Tehran, Iran.
Who may be able to join
- -BC patients diagnosed between January 1998 and February 2008 in the Motamed Breast Cancer Research in Tehran, Iran.
Who cannot join
- Male patients.
- Patients with missing LPFS and OS information (zero encounter/follow-up).
About this study
Official title: Impact of Radiotherapy on Disease-Free and Overall Survival in Breast Cancer Patients: A Retrospective Cohort Study
In this study, using a large retrospective cohort, the investigators evaluate the impact of RT on disease-free survival and overall survival of patients with BC. The aim is to determine the true role of radiotherapy in improving patient outcomes and to provide a basis for designing more precise treatment strategies in the future.
- Conditions
- Breast Cancer, Radiotherapy
- Being tested
- radiotherapy
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
radiotherapyRadiation
Radiotherapy after BCS surgery in accordance to standard breast cancer guidelines
| Study group | Role | What they receive |
|---|---|---|
| Breast Cancer Patients who underwent RT | Not described Receives: Radiation: radiotherapy | |
| Breast Cancer Patients who did not underwent RT | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Survival
Measured: 25 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jun 2026
- Study start1 Jan 1998
- Primary completion1 Feb 2008
- Study completion1 Jan 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case crossover
- Time perspective
- Retrospective
- Enrolment
- 1,030 participants (actual)
Sponsor and investigators
- Lead sponsor
- Motamed Cancer Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Fereshteh Abbasvandi, Motamed Cancer Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07631962
- Sponsor's protocol ID
- IR.SUMS.REC.1405.141
- Status last verified
- Jun 2026
- First submitted
- 28 May 2026
- Last updated
- 8 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Radiotherapy on Disease-Free and Overall Survival in Breast Cancer Patients: A Retrospective Cohort Study
- ClinicalTrials.gov ID
- NCT07631962
- Acronym / sponsor ID
- IR.SUMS.REC.1405.141
- Conditions
- Breast Cancer, Radiotherapy
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,030 participants (actual)
- Lead sponsor
- Motamed Cancer InstituteUniversity, hospital or other
- Study start
- 1 Jan 1998 (actual)
- Primary completion
- 1 Feb 2008 (actual)
- Study completion
- 1 Jan 2025 (actual)
- First posted
- 8 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In this study, using a large retrospective cohort, the investigators evaluate the impact of RT on disease-free survival and overall survival of patients with BC. The aim is to determine the true role of radiotherapy in improving patient outcomes and to provide a basis for designing more precise treatment strategies in the future.
Study design
- Observational model
- Case crossover
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Breast Cancer Patients who underwent RT | – | Radiation: radiotherapy |
| Breast Cancer Patients who did not underwent RT | – | – |
Who may qualify
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- BC patients diagnosed between January 1998 and February 2008 were identified from prospectively maintained breast cancer registries in the Motamed Breast Cancer Research in Tehran, Iran.
Key inclusion criteria (1 listed)
- -BC patients diagnosed between January 1998 and February 2008 in the Motamed Breast Cancer Research in Tehran, Iran.
Key exclusion criteria (2 listed)
- Male patients.
- Patients with missing LPFS and OS information (zero encounter/follow-up).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| radiotherapyRadiotherapy after BCS surgery in accordance to standard breast cancer guidelines | Radiation | Breast Cancer Patients who underwent RT |
Primary outcome
Survival
Time frame: 25 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jun 2026.
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Breast Cancer and Radiotherapy, run by Motamed Cancer Institute.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Survival (time frame: 25 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jun 2026; AzTrials last refreshed its copy on 8 Nov 2026.